Glomerulonephritis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Glomerulonephritis – Drugs In Development, 2023’, provides an overview of the Glomerulonephritis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Glomerulonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glomerulonephritis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Glomerulonephritis
- The report reviews pipeline therapeutics for Glomerulonephritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Glomerulonephritis therapeutics and enlists all their major and minor projects
- The report assesses Glomerulonephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Glomerulonephritis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Glomerulonephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Glomerulonephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Acelyrin IncAkebia Therapeutics Inc
AKSO Biopharmaceutical Inc
Alexion Pharmaceuticals Inc
Algomedix Inc
Alnylam Pharmaceuticals Inc
Alpine Immune Sciences Inc
Amgen Inc
Amyndas Pharmaceuticals LLC
Anagenics Ltd
Apellis Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc
Augusta University
Bayer AG
Beijing Puqi Pharmaceutical Technology Co Ltd
BioCryst Pharmaceuticals Inc
Biohaven Ltd
Boehringer Ingelheim International GmbH
Cabaletta Bio Inc
Calliditas Therapeutics AB
Ceptur Therapeutics Inc
Cerium Pharmaceuticals Inc
Certa Therapeutics Pty Ltd
Chinook Therapeutics Inc
Coegin Pharma AB
Createrna Science and Technology Co Ltd
Delta 4 GmbH
DiaMedica Therapeutics Inc
Dimerix Ltd
Eli Lilly and Co
Ergon Pharmaceuticals LLC
Everest Medicines Ltd
F. Hoffmann-La Roche Ltd
Generian Pharmaceuticals Inc
Gmax Biopharm LLC
Goldfinch Bio Inc
Haisco Pharmaceutical Group Co Ltd
Horizon Therapeutics Plc
Human Immunology Biosciences Inc
ImmunoWork LLC
Innovent Biologics Inc
InSilico Medicine
Integral Molecular Inc
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Jiangsu Hengrui Medicine Co Ltd
KBP Biosciences Co Ltd
KeyMed Biosciences Inc
Kira Pharmaceuticals
Lempo Therapeutics Ltd
Lepton Pharmaceuticals Ltd
Lotus Pharmaceutical Co Ltd
Novartis AG
NovelMed Therapeutics Inc
OccuRx Pty Ltd
Omeros Corp
Oraxion Therapeutics Inc
PlateletBio
Protheragen Inc
Puretech Health Plc
Ra Pharmaceuticals Inc
RemeGen Co Ltd
River 3 Renal Corp
Rohto Pharmaceutical Co Ltd
Rona Therapeutics Inc
SanReno Therapeutics
Shanghai Alebund Pharmaceuticals Ltd
Shanghai Fosun Pharmaceutical (Group) Co Ltd
Shanghai Meiji Biotechnology Co Ltd
Shenzhen Crystal Egg Biomedical Technology Co Ltd
Shenzhen Evergreen Therapeutics Co Ltd
Slate Bio Inc
Sujana Biotech
LLC
Surrozen Inc
Takeda Pharmaceutical Co Ltd
The Sydney Children's Hospitals Network
The United Laboratories International Holdings Ltd
Tohoku University
Transcenta Holding Ltd
Travere Therapeutics Inc
Vera Therapeutics Inc
Vertex Pharmaceuticals Inc
Viatris Inc
Visterra Inc
Wuxi Biocity Biopharma Co Ltd
Zai Lab Ltd
Zenyaku Kogyo Co Ltd
ZyVersa Therapeutics Inc